对阿尔茨海默病的了解:从基本见解到临床前研究
Jie Mi1, Chao Liu1,2,3, Honglei Chen1
1Yiwu Research Institute, Fudan University, Yiwu, China.
Frontiers in aging neuroscience
|April 3, 2024
概括
光声学成像 (PA) 为诊断和治疗阿尔茨海默病 (AD) 提供了一种新的方法. 这种混合成像技术可视化大脑的变化,为早期检测和改进的治疗策略铺平了道路.
科学领域:
- 生物医学成像技术 生物医学成像技术
- 神经科学是一个神经科学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 阿尔茨海默病 (AD) 是一种渐进性的认知衰退障碍,对全球健康和经济构成重大挑战.
- 随着阿尔茨海默病的患病率不断上升,需要先进的诊断和成像工具来更好地理解和管理.
- 光声学 (PA) 影像,一种混合模式,将光学对比度与超声波深度相结合,对阿尔茨海默氏症研究具有前景.
研究的目的:
- 在阿尔茨海默病的诊断和治疗中提供PA成像现有和潜在应用的全面审查.
- 要总结AD相关的大脑成像中可通过PA成像检测到的结构,功能和分子变化.
- 讨论AD的治疗策略,并探索PA成像的未来临床应用.
主要方法:
- 对阿尔茨海默病研究中PA成像应用现有文献的综述.
- 分析PA成像的能力,以可视化与AD相关的神经病理变化.
- 探索AD治疗干预措施与PA成像模式的结合.
主要成果:
- PA成像显示了组织结构的高分辨率可视化以及与AD相关的多功能信息.
- 初步结果表明PA成像在研究和诊断阿尔茨海默病的潜力.
- PA成像可以捕捉与AD相关的大脑中的结构,功能和分子变化.
结论:
- PA成像为阿尔茨海默病的诊断和治疗监测提供了一个有前途的工具.
- 需要进一步的研究和临床应用,以充分利用PA成像用于早期AD检测和治疗术.
- 本综述强调了PA成像在解决阿尔茨海默病带来的挑战方面的创新潜力.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
